PeptiGrowth, Inc
PeptiGrowth Inc., based in Tokyo, Japan, was developed through the co-funding of Mitsubishi Corporation and PeptiDream Inc in April 2020. PeptiGrowth Inc. has been dedicated to the development of a series of synthetic peptide growth factors that possess equivalent activities and functions as conventional growth factors and cytokines, leveraging PeptiDream’s proprietary technology called PDPS (Peptide Discovery Platform System). Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products face various challenges such as lot-to-lot quality variations, potential contamination with biological impurities, low stability, and high manufacturing costs. PeptiGrowth’s synthetic peptide growth factors can address and resolve all these challenges. These peptides possess higher stability than conventional growth factors and cytokines and are completely chemically synthesized, making them animal component-free with the capability of being produced in GMP grade. The high scalability of peptide synthesis can significantly reduce production costs, making it possible to provide synthetic peptide growth factors at more reasonable prices than recombinant-based growth factors and cytokines. By the end of March 2024, we have launched the following 10 products: PG-001: HGF alternative peptide PG-002: TGF beta 1 inhibitor PG-003: BDNF alternative peptide PG-004: Noggin-like peptide PG-005: BMP7 selective inhibitor PG-006: BMP4 selective inhibitor PG-007: VEGF alternative peptide PG-008: Wnt3a alternative peptide PG-009: Synthetic EGF (human) PG-010: TPO alternative peptide More products will be launched in the upcoming years, including alternative peptides for FGF2 (bFGF), PDGF-AA, KGF, IL-15, etc.
